Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 12/20 | 0.62 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655469 | 0.87 | FGFR4 (0.49) | FGFR4FGFR3FGFR1FGFR2CYP3A4 | |
| SCHEMBL16654547 | 0.83 | FGFR4 (0.59) | FGFR4FGFR3FGFR1FGFR2CYP3A4 | |
| SCHEMBL374172 | 0.83 | FGFR4 (0.74) | FGFR4FGFR3FGFR1FGFR2CYP3A4 | |
| SCHEMBL16654099 | 0.82 | FGFR4 (0.55) | FGFR4FGFR3FGFR1CYP3A4CYP2C19 | |
| SCHEMBL28616991 | 0.80 | FGFR4 (0.53) | FGFR4FGFR3FGFR1FGFR2CYP3A4 | |
| SCHEMBL18131081 | 0.79 | FGFR4 (0.54) | FGFR4FGFR3FGFR1FGFR2CYP3A4 | |
| SCHEMBL16659464 | 0.78 | FGFR4 (1.00) | FGFR4FGFR3FGFR1FGFR2 | |
| SCHEMBL374404 | 0.76 | FGFR4 (0.62) | FGFR4FGFR3FGFR1CYP3A4CYP2C19 | |
| SCHEMBL374461 | 0.76 | LCK (0.77) | FGFR4FGFR3FGFR1CYP3A4CYP2C19 | |
| SCHEMBL374136 | 0.74 | FGFR3 (0.84) | FGFR4FGFR3FGFR1FGFR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093972-A1 | CRYSTALLINE FGFR4 INHIBITOR COMPOUND AND USES THEREOF | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR3 3/4885FGFR1 2/4885 |
| US-10562888-B2 | Crystalline FGFR4 inhibitor compound and uses thereof | FGFR4, FGFR1, FGFR3 | FGFR4 1/4885FGFR3 3/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.